A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms

Sworder et al.1 developed an integrated simultaneous tumor and effector profiling (STEP) approach to study resistance mechanisms to CD19-CAR T cell therapy in large B-cell lymphomas. Their study provides novel biological insights and paves the way for future interventions. Sworder et al.1 developed...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports. Medicine 2023-02, Vol.4 (2), p.100949-100949, Article 100949
Main Authors: Talleur, Aimee C., Gottschalk, Stephen
Format: Article
Language:English
Subjects:
Biochemical Phenomena
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell
Spotlight
T-Lymphocytes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sworder et al.1 developed an integrated simultaneous tumor and effector profiling (STEP) approach to study resistance mechanisms to CD19-CAR T cell therapy in large B-cell lymphomas. Their study provides novel biological insights and paves the way for future interventions. Sworder et al.1 developed an integrated simultaneous tumor and effector profiling (STEP) approach to study resistance mechanisms to CD19-CAR T cell therapy in large B-cell lymphomas. Their study provides novel biological insights and paves the way for future interventions.
ISSN:2666-3791
2666-3791
DOI:10.1016/j.xcrm.2023.100949